EUCTR2008-008314-40-DE进行中（未招募）不适用
Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 276
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects, or their legal representative(s), must have given their written informed consent to participate in the study after receiving adequate previous information and prior to any study specific procedures
- •Adults =18 years
- •Documented diagnosis of CF:
- •-documented sweat chloride =60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) or nasal potential difference
- •-or either homozygous for ?F508 genetic mutation or a compound heterozygous for 2 known CF mutations
- •-and clinical findings consistent with CF
- •Chronic colonization with P aeruginosa defined as a positive respiratory tract culture (sputum or throat swab) within 12 months prior to screening and at screening (Note: subjects with negative culture at screening can, at the discretion of the investigator, be rescreened at a later date)
- •Ability to perform reproducible pulmonary function tests
- •Ability to produce sputum (noninduced)
- •Stable pulmonary status, FEV1 =35% to =75% (intraindividual variability ±10% of absolute value). Note: The subject is not eligible for enrollment if the variability results in (or leads to) an FEV1 <35%.
- •Room air oximetry =88% saturation
- •Off antibiotics (except macrolide) and Cipro (oral) for at least 30 days prior to the administration of study drug for pulmonary exacerbation. Non-antipseudomonal antibiotics administered for other indications are allowed.
- •Stable regimen of standard CF treatment including chest physiotherapies and exercise regimens should not change during the 30 days prior to the administration of study drug and during the study (including macrolide administration unchanged in the previous 30 days)
- •Subjects who are able to understand and follow instructions and who are able to participate in the study for the entire period
- •Women who are willing to use an adequate method of contraception for 3 months after receiving the study drug. Adequate methods of contraception include vasectomy or condom use by their partners, diaphragm with spermicidal gel, coil (intrauterine device), surgical sterilization or oral contraceptive.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Findings on screening history and physical examination unrelated to CF that could potentially affect the efficacy measurements (eg, chest surgery)
- •Subjects with colonization of P aeruginosa and a CIPRO MIC of =256 µg/ml or mg/l
- •Burkholderia cepacia complex colonization of their respiratory tract within the past 12 months (documented by screen laboratory)
- •Known aspergillosis (unless asymptomatic). Patients with invasive disease, ABPA with IgE > 500 mg/dL will be excluded.
- •Transaminase level >3x upper limit of normal (ULN)
- •Massive hemoptysis (=300 cc or requiring blood transfusion) in the preceding 4 weeks
- •IV antibiotic treatment for pulmonary exacerbation in the past 30 days prior to the first study drug administration
- •Subjects with a medical disorder, condition or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator or the sponsor
- •Febrile illness within 1 week before the start of the study
- •Active treatment for nontuberculosis mycobacteria
- •Exposure to any investigational drug within 30 days
- •Any history of allergic reaction to fluoroquinolones or other quinolones
- •On oral steroids >20 mg/day for longer than 14 days in the past 3 months
- •Creatinine =2x ULN
- •Subjects with a history of severe allergies, severe non-allergic drug reactions, or severe multiple drug allergies (i.e. severe allergies to multiple classes of drugs or multiple drug regardless of class)
- •Female subjects who are pregnant, lactating or in whom pregnancy cannot be excluded (Note: a urine pregnancy test will be performed on all women of childbearing potential before inclusion in the study, followed by serum pregnancy test.)
研究者
相似试验
进行中（未招募）
1 期
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non-CF BE)bronchiectasisMedDRA version: 14.1Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-004208-39-ESBayer HealthCare AG300
进行中（未招募）
1 期
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non–CF BE)non-CF bronchiectasisMedDRA version: 19.0Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-004659-19-DEBayer AG492
进行中（未招募）
不适用
Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH). - PATENT-1 StudyPulmonary Arterial Hypertension (PAH)MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-003482-68-DKBayer HealthCare AG, D-51368 Leverkusen462
进行中（未招募）
1 期
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non–CF BE)bronchiectasisEUCTR2011-004208-39-ITBAYER HEALTHCARE AG300
进行中（未招募）
1 期
Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH). - PATENT-1 StudyPulmonary Arterial Hypertension (PAH)MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-003482-68-BEBayer HealthCare AG, D-51368 Leverkusen462